Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients

Hepatology

Volumn 37, Issue 3, 2003, Pages 568-576

  Liu, Chun Jen ^a   Chen, Pei Jer ^a   Lai, Ming Yang ^a   Kao, Jia Horng ^a   Jeng, Yung Ming ^a   Chen, Ding Shinn ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; SUPERINFECTION; TREATMENT OUTCOME;

EID: 84984567329     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50096     Document Type: Article

References (42)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
2. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990;162:817-822.
3. Tsai JF, Jeng JE, Chang WY, Lin ZY, Tsai JH. Hepatitis C virus infection among patients with chronic liver disease in an area hyperendemic for hepatitis B. Scand J Gastroenterol 1994;29:651-654.
4. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. HEPATOLOGY 1995;22:1101-1108.
5. Pramoolsinsap C, Sirikulchayanonta V, Busakorn W, Poovorawan Y, Hirsch P, Theamboonlers A, Lerdverasirikul P. Coinfections with hepatitis G and/or C virus in hepatitis B-related chronic liver disease. Southeast Asian J Trop Med Public Health 1999;30:741-749.
6. Sagnelli E, Felaco FM, Filippini P, Scolastico C, Rapicetta M, Stroffolini T, Piccinino F. Multiple hepatitis virus infections in chronic HBsAg carriers in Naples. Arch Virol 1997;142:445-451.
7. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-354.
8. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.
9. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995;332:1457-1462.
10. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-1499.
11. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-87.
12. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
13. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
14. Liaw YF, Chien RN, Lin SM, Yeh CT, Tsai SL, Sheen IS, Chu CM. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997;17:449-452.
15. Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, Liddle C. Coinfection with hepatitis B and C or B, C, and delta viruses results in severe chronic liver disease and responds poorly to interferon alpha treatment. J Viral Hepat 1995;2:39-45.
16. Mazzella G, Saxacco G, Festi D, Rosina F, Maxchetto S, Jaboli F, Sostegni R, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999;94:2246-2250.
17. Guptan RC, Thakur V, Raina V, Sarin SK. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 1999;14:893-898.
18. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: Long term results of a prospective randomized trial. Am J Gastroenterol 2001; 96:2973-2977.
19. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, Michielsen PP, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999;117: 408-413.
20. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
21. Ryff JC. Usefulness of interferon for treatment of hepatitis C. J Hepatol 1995;22(Suppl 1):101-109.
22. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, Sulkowski MS, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously non-responsive to interferon. A meta-analysis of randomized trials. JAMA 2001;285:193-199.
23. Kao JH, Lin HH, Chen PJ, Lai MY, Wang TH, Mizokami M, Chen DS. Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: correlation with genotypes. J Gastroenterol 1996;31:224-227.
24. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel DH. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000;95:3529-3536.
25. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-26.
26. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000;118:346-355.
27. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999;30:376-382.
28. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998;79: 2381-2391.
29. Fang SH, Chiang BL, Wu MH, Iba H, Lai MY, Yang PM, Chen DS, et al. Functional measurement of hepatitis C virus core-specific CD8(+) T-cell responses in the livers or peripheral blood of patients by using autologous peripheral blood mononuclear cells as targets or stimulators. J Clin Microbiol 2001;39:3895-3901.
30. Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000;33:791-798.
31. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem. 2001;49:46094-46098.
32. Lau JYN, Tam RC, Liang TJ, Hong Z. Mecahnism of action of ribavirin in the combination treatment of chronic HCV infection. HEPATOLOGY 2002; 35:1002-1009.
33. Bergamini A, Bolacchi F, Cepparulo M, Demin F, Uccella I, Bongiovanni B, Ombres D, et al. Treatment with ribavirin and interferon-α reduces interferon-γ expression in patients with chronic hepatitis C. Clin Exp Immunol 2001;123:459-464.
34. Manns M, McHutchinson J, Gordon S, Rustgi V, Shiffman M, Reindollar R, Goodman Z, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001:358:958-965.
35. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced hemolytic anemia in patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1623-1632.
36. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18.
37. National Institute of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-June 10-12, 2002. HEPATOLOGY 2002;36:S3-S20.
38. Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, Onofrio M, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. HEPATOLOGY 2002;36:1285-1291.
39. Tsai SL, Liaw YF, Yeh CT, Chu CM, Kuo GC. Cellular immune responses in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus. HEPATOLOGY 1995;21:908-912.
40. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
41. Dries V, von Both I, Muller M, Gerken G, Schirmacher P, Odenthal M, Bartenschlager R, et al. Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. HEPATOLOGY 1999;29:223-229.
42. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. HEPATOLOGY 2000;32:818-823.